Thymosin Alpha-1 Explored for Immune Side Effects of Cancer Immunotherapy
Thymosin Alpha-1 for irAE Secondary to ICIs
Abstract
A Prospective, Open, Randomized Controlled Stage II Trial Investigating the Efficacy and Safety of Thymosin Alpha-1 in Treating Moderate to Severe Immune-related Adverse Events
NCT ID: NCT06178146
Status: UNKNOWN
Sponsor: Jun Wang
Start: 2…